RxDoctor Payments Data

Carol Traphagan, APRN

Adult Health · Fayetteville, ARNPI 1326152448

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.

$2,934in general payments, 2019–2025

Across 127 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$589
  • Pfizer$422
  • Amgen$382
  • Abbott$276
  • Novo Nordisk$225
  • Merck$200
  • plus $840 from 13 others

What the payments were for

  • Food & beverage$2,934100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,934 in reported general payments places this provider in the 80th percentile of 154 adult health providers in Arkansas.

See all adult health providers in Arkansas

Medicare billing

Part B allowed, 2024
$27,989
Medicare patients
100
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan145$164,685
EliquisApixaban71$91,555
JardianceEmpagliflozin100$82,146
Repatha SureclickEvolocumab84$71,479
FarxigaDapagliflozin Propanediol48$45,533
Metoprolol Succinate113$1,675
Potassium Chloride67$1,383
Ezetimibe76$1,126
Atorvastatin Calcium93$1,087
Spironolactone186$945
Carvedilol149$888
Furosemide143$832
Nebivolol Hcl12$731
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$511
Torsemide44$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$589$164,685145 claims
PfizerEliquis$422$91,55571 claims
AstraZenecaFarxiga$54$45,53348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 adult health providers in Arkansas.

Other adult health in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →